Abstract: The present invention relates to methods for determining the concentration of a free beta-lactam antibiotic in a biological sample. In particular, the present invention relates to methods for measuring a free beta-lactam antibiotic in a biological sample, comprising the steps of: (a) providing at least one class C beta-lactamase, a functional fragment or variant thereof; (b) providing at least one biological sample; (c) contacting said at least one class C beta-lactamase with said at least one biological sample; and (d) determining the concentration of said free beta-lactam antibiotic in said at least one biological sample.

Abstract: The present invention relates to methods for determining the concentration of a free beta-lactam antibiotic in a biological sample. In particular, the present invention relates to methods for measuring a free beta-lactam antibiotic in a biological sample, comprising the steps of: (a) providing at least one class C beta-lactamase, a functional fragment or variant thereof; (b) providing at least one biological sample; (c) contacting said at least one class C beta-lactamase with said at least one biological sample; and (d) determining the concentration of said free beta-lactam antibiotic in said at least one biological sample.

Abstract: The present invention relates to azo dyes, in particular azo dyes of Formula (I) or (II), a tautomer, a quaternary amine, or a salt thereof, wherein R1, R2a, R2b, R3, R4, R5, R3, R7, R8, R9, R10, R11 have the same meaning as in the claims. The present invention also relates to processes for preparing said compounds, compositions containing them and their use as dyes.

Abstract: The present invention concerns highly water-soluble phenoxazines dyes of formula (I) wherein R1, R2, R3, R4, R5 and R6 have the meaning defined in the claim, with improved photochemical properties, low toxicity, and favourable solubility in water. It also concerns a method for their preparation.

Abstract: The present invention relates to chemical synthesis of radiolabelled perfluorinated bioactive compounds. More particularly, the present invention relates to radiolabelled compounds to be used as indicators for tissue hypoxia. More particularly, the present invention relates to the synthesis and the use of [18F] labelled perfluorinated nitroimidazole compounds having an incorporation of [18F] atoms characterized by a specific radioactivity of the compound comprised between 1 and 30 Ci/mmol, preferably between 1 and 20 Ci/mmol, preferably 1 and 10 Ci/mmol. More particularly to [18F] labelled EF3 or [18F] labelled EF5. The present invention also relates to a method for the detection of tissue hypoxia in a patient comprising introducing an [18F] labelled nitroimidazole compound into said patient, imaging tissue hypoxia in said patient, and, quantifying tissue hypoxia in said patient.

Abstract: The present invention relates to an aryl substituted pyrazine compound of the general formula I, II, III or IV with the exception of a) 2-amino-3,5-bis(p-methoxyphenyl)-1,4-pyrazine (CD29), 2-amino-5-phenyl-1,4-pyrazine (CD12), 2-amino-5-(4-methoxyphenyl)-1,4-pyrazine (CD17) and 2-amino-5-(4-hydroxyphenyl)-1,4-pyrazine (CD22) and of b) their corresponding imidazolopyrazinone compounds. Another aspect of the invention relates to anti-oxidant compounds of formula V. Another aspect of the invention is a compound which upon oxidation results via a cascade in a second anti-oxidant compound and a third compound.

Abstract: The present invention relates to a method for the preparation of a compound of the general formula (I) wherein